CD47 as a therapeutic target for obesity

棕色脂肪组织（BAT）通过UCP 1介导的解偶联呼吸及其激活耗散能量 可能代表了一种对抗肥胖的治疗策略。初步研究确定了CD 47的新作用 调节BAT功能及其对能量稳态和肥胖发展的贡献。 CD 47是一种广泛表达的细胞膜受体，与自我识别和免疫功能有关， 在肥胖动物的脂肪组织中表达上调。此外，CD 47缺陷保护小鼠免受饮食- 通过激活BAT功能（例如，增强线粒体解偶联和加热）诱导肥胖（DIO） 生产）和增加的能源消耗。这些数据表明，CD 47是BAT的负调节因子。 活动因此，抑制CD 47信号传导可能是一种新的抗肥胖策略，这是进一步的研究。 最近的一项人类全基因组研究表明，单核苷酸多态性 CD 47基因与体重、BMI的相关性。在这项提议中，CD 47下调 棕色脂肪细胞功能将在目标1中确定。棕色脂肪细胞特异性CD 47的表达 将在目标2中确定缺乏对肥胖发展的影响。是否通过CD 47 - 1抑制CD 47信号传导 反义寡核苷酸（阿索）治疗激活BAT并预防/改善动物肥胖发展 模型将在目标3中确定。这些研究不仅将提供新的信息的机制 CD 47通过其下调棕色脂肪功能及其对能量稳态的贡献， 本发明的目的不仅在于测试CD 47-ASO在肥胖小鼠模型中的抗肥胖潜力，还在于测试CD 47-ASO在肥胖小鼠模型中的抗肥胖潜力。 因此，这些研究具有临床意义。

Brown adipose tissue (BAT) dissipates energy through UCP1-mediated uncoupled respiration and its activation may represent a therapeutic strategy to combat obesity. Preliminary studies identified a novel role of CD47 in regulating BAT function and its contribution to energy homeostasis and the development of obesity. CD47, a ubiquitously expressed cell membrane receptor implicated in self-recognition and immune function, was upregulated in adipose tissue from obese animals. Moreover, CD47 deficiency protected mice from diet- induced obesity (DIO) through activation of BAT function (e.g. enhanced mitochondria uncoupling and heat production) and increased energy expenditure. These data suggest that CD47 is a negative regulator of BAT activity. Therefore, inhibition of CD47 signaling might be a novel anti-obesity strategy, which is further supported by a recent human genome-wide study showing the association of single-nucleotide polymorphisms in CD47 gene with body weight and BMI. In this proposal the mechanisms by which CD47 downregulates brown fat cell function will be determined in Aim 1. The contribution of brown adipocyte specific CD47 deficiency on obesity development will be determined in Aim 2. Whether inhibition of CD47 signaling by CD47- antisense oligo (ASO) treatment activates BAT and prevents/ameliorates obesity development in animal models will be determined in Aim 3. These studies will not only provide novel information on the mechanisms by which CD47 down-regulates brown fat function and its contribution to energy homeostasis and the development of obesity, but also test the anti-obesity potential of a CD47-ASO in obese mouse models. Therefore these studies have clinical significance.